Chemotherapeutic vandetanib bound to its main target, Protein Tyrosine Kinase 6, or PTK6, in purple, which is involved in many cancers including gastrointestinal tumors and ovarian cancers. By modeling vandetanib and PTK6 complex, researchers at LSU found the KRAS protein to also contain a similar drug-binding site and therefore to be a good match for the same drug. The computer-generated model of KRAS in gold with vandetanib depicts the predicted interaction.
Photo Credit: Misagh Naderi, LSU.
One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
Learn more: Researchers Computationally Find the Needle in a Haystack to Treat Rare Diseases
The Latest on: Drug repositioning
via Google News
[/vc_column_text][/vc_column]
The Latest on: Drug repositioning
- Burns Scalo considering second life sciences building at Pittsburgh Technology Center in South Oaklandon August 24, 2021 at 3:33 pm
Jim Scalo has received an expensive education in repositioning Burns Scalo Real Estate's Riviera project from the traditional office building it started as into one accommodating new wet lab uses for ...
- 35 Stocks Moving In Monday's Mid-Day Sessionon August 23, 2021 at 12:02 pm
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
- Vivos: FDA Denies Additional 510(k) Application for DNA Applianceon August 23, 2021 at 5:30 am
By Michael Dabaie Vivos Therapeutics Inc. said the U.S. Food and Drug Administration denied a previously submitted additional 510(k) application for its ...
- Repositioning Victorian Sciences: Shifting Centres in Nineteenth-Century Thinkingon August 23, 2021 at 2:42 am
Although sea serpents are most often associated with myth and legend, in the nineteenth century... 4 ‘THE DRUGS, THE BLISTER AND THE LANCET ARE ALL LAID ASIDE’: HYDROPATHY AND MEDICAL ORTHODOXY IN ...
- Vivos Says FDA Gives Market Clearance to Sleep-Apnea Applianceon August 23, 2021 at 12:31 am
Vivos Therapeutics Inc. said the U.S. Food and Drug Administration granted 510(k) market clearance to Vivos's modified mandibular Repositioning Nighttime Appliance device for treating mild to moderate ...
- Repositioning Kogi civil serviceon August 4, 2021 at 6:42 pm
Before her appointment, she was a deputy director with the National Agency for Food and Drug Administration and Control (NAFDAC). Few weeks after her resumption at Lokoja, the state capital ...
- Repositioning Healthcare Deliveryon August 4, 2021 at 5:38 pm
Drug availability is also a cause for concern, with less than half of all Primary Healthcare Centre (PHC) facilities having the listed essential drugs in stock. Healthcare is majorly driven by the ...
- Drug Repositioning Market Proceeds To Witness Huge Upswing Over Assessment Period by 2030on August 3, 2021 at 3:59 am
The Global Drug Repositioning Market Report makes available the current and forthcoming technical and financial details of the industry. The report contains an in-depth analysis of market ...
- Current ADDF Drug Discovery grantson July 29, 2021 at 5:00 pm
This international collaboration offers up to $1.5 million for research projects that focus on repurposing or repositioning existing drugs to see if they can benefit people affected by dementia. You ...
via Bing News
